b'Quality data, faster.Reduce time of study with pre-optimized panels and analysis templatesSeveral clinical trials 10,11have used the Maxpar Direct Immune Profiling Assay (MDIPA) for its comprehensive and convenient immunophenotyping screening in a single assay. MDIPA is a lyophilized and validated 30-marker antibody panel, that can be easily combined with expansion panels and an automated five-minute analysis solution to quickly identify cell types and cell differentiation states. CASE STUDYScalable immune profiling in clinical trials with CyTOF reagentsIn one Phase I/II multiple myeloma trial 10 , this assay was customized with six additional markers to find correlates of response and resistance following TIGITLAG3 blockade.Highlights of MDIPAValidated andCycle 1 Cycle 2 ready-to-go assayAnti-LAG-3 Anti-LAG-3 + Pom Automated 5-min Relapsed MMdata analysisCycle 1 Cycle 2Anti-TIGIT Anti-TIGIT + PomBlood BoneResponderResponderNonresponder marrow LAG3 Arm TIGIT Arm LAG3 or TIGIT ArmFigure 4. Rapid and comprehensive immunophenotyping with MDIPA for two study arms and at different time points generated important insights into the distinct clinical response pathways associated with TIGIT or LAG3 blockade resistance.'